New combo therapy shows promise in preventing stroke worsening

NCT ID NCT06696820

Completed Disease control Sponsor: Xiang Luo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving a powerful cholesterol-lowering drug (evolocumab) along with standard statins within 48 hours of a stroke could prevent early neurological decline. It included 429 adults with moderate to severe narrowing of brain arteries. The goal was to see if the combo reduces worsening of symptoms and improves recovery over 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Evolocumab (a PCSK9 inhibitor) combined with atorvastatin or rosuvastatin
What this could lead to: If successful, this combination could become a standard early treatment to prevent neurological worsening after a stroke caused by narrowed brain arteries.
What could go wrong: This is a Phase 2/3 trial with 429 participants, so results are still preliminary. The open-label design may introduce bias, and there is a risk of bleeding or other side effects from the drug combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intracranial arterial disease ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.